Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure (DAPTLong)
A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure
Sponsor: Genoss Co., Ltd.
A observational or N/A phase clinical study on Coronary Artery Disease and Dual Antiplatelet Therapy, this trial is actively recruiting participants. The trial is conducted by Genoss Co., Ltd. and has accumulated 5 data snapshots since 2022. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Mar 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Nov 2023 — Jul 2024 [monthly]
Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genoss Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .